Injection site rotation (revision 21)
Old revision·00:57, 12 Jan 2026·MissedDoseMik
| Injection site rotationAdministration practice | |
|---|---|
| Problem addressed | Lipohypertrophy and erratic absorption |
| Within-region rotation | Preserves regional absorption characteristics |
| Between-region rotation | Changes absorption characteristics as well |
| Topic infobox · conventions | |
Injection site rotation is the practice of varying the location of successive subcutaneous injections. Its purpose is to avoid the local tissue changes that repeated injection at one point produces, principally lipohypertrophy — a thickening of the subcutaneous tissue from which absorption becomes erratic.[1]
The evidence base is largely from insulin therapy, where lipohypertrophy is common, is associated with unpredictable glycaemic control, and resolves slowly when the affected area is rested. Its relevance to weekly peptide administration is less well characterised, since injection frequency is roughly one seventh of that in basal-bolus insulin therapy.[2]
Two rotation patterns are distinguished. Rotating within a region — moving a couple of centimetres each time while staying in the same anatomical area — preserves that region's absorption characteristics. Rotating between regions changes them as well.[1]
Lipohypertrophy
[edit]Lipohypertrophy is a local proliferation of subcutaneous adipose tissue at sites of repeated injection. It presents as a soft or rubbery thickening, often more readily felt than seen, and is frequently painless — which is part of why it is under-recognised.[2]
Absorption from affected tissue is reduced and more variable. In insulin therapy this produces unexplained variability that persists until the affected area is rested, and continued injection into it is self-reinforcing because reduced sensation makes the site attractive.
Whether repeated weekly injection of a peptide produces the same lesion is not established. Frequency is much lower, but the mechanical and pharmacological insults are qualitatively similar, and the literature on this specific question is thin.[3]
Rotation schemes
[edit]The schemes described in the insulin literature divide each anatomical region into quadrants or a grid, use one region for a defined period, and move within it by a fixed distance each time before moving to the next region.[1]
| Pattern | Effect |
|---|---|
| Within-region, fixed spacing | Spreads mechanical insult; absorption profile stable |
| Between-region each time | Spreads insult; absorption profile varies between doses |
| No rotation | Concentrates insult at one point |
For a preparation whose absorption is not rate-limiting — a weekly albumin-bound peptide, for example — the second pattern's variability is of little consequence, and the choice between the first two is not clinically significant on pharmacokinetic grounds.[3]
This article describes practices reported in the clinical literature. It is not medical advice, and research-use compounds are not approved for human administration.
Related considerations
[edit]Needle reuse compounds local trauma, since a needle blunts measurably after a single insertion and a blunted needle produces more tissue damage on the next. See Insulin syringe.[1]
Sites with visible or palpable abnormality, scarring, or inflammation are avoided in reported practice, as are areas that will be subject to unusual local blood flow shortly after injection.[4]
Documented site records — a simple log of which site was used when — are the mechanism by which rotation is actually achieved in the studies that examined it. Rotation intended but not recorded tends in practice to cluster.[2]
See also
References
- ^ a b c d American Diabetes Association. "Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
- ^ a b c Gentile S, Strollo F, Ceriello A. "Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear?" Diabetes Therapy 7(3):401–409 (2016). PMID 27503118.
- ^ a b Richter WF, Bhansali SG, Morris ME. "Mechanistic determinants of biotherapeutics absorption following SC administration." The AAPS Journal 14(3):559–570 (2012). PMID 22619043.
- ^ United States Pharmacopeia, General Chapter <797>, Pharmaceutical Compounding — Sterile Preparations.